BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tarasco E, Bütikofer L, Friedman KD, George JN, Hrachovinova I, Knöbl PN, Matsumoto M, von Krogh AS, Aebi-Huber I, Cermakova Z, Górska-Kosicka M, Jalowiec KA, Largiadèr CR, Prohászka Z, Sinkovits G, Windyga J, Lämmle B, Kremer Hovinga JA. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood 2021;137:3563-75. [PMID: 33649760 DOI: 10.1182/blood.2020009801] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Woods AI, Paiva J, Dos Santos C, Alberto MF, Sánchez-luceros A. From the Discovery of ADAMTS13 to Current Understanding of Its Role in Health and Disease. Semin Thromb Hemost 2022. [DOI: 10.1055/s-0042-1758059] [Reference Citation Analysis]
2 Markham-lee Z, Morgan NV, Emsley J. Inherited ADAMTS13 mutations associated with Thrombotic Thrombocytopenic Purpura: a short review and update. Platelets 2022. [DOI: 10.1080/09537104.2022.2138306] [Reference Citation Analysis]
3 Tarasco E, von Krogh AS, Hrdlickova R, Braschler TR, Iwaniec T, Knöbl PN, Hamada E, Pikovsky O, Farese S, Gutwein O, Kessler P, Schultz NH, von Auer C, Windyga J, Friedman K, Hrachovinova I, George JN, Matsumoto M, Schneppenheim R, Lämmle B, Kremer Hovinga JA. Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease. Res Pract Thromb Haemost 2022;6:e12814. [PMID: 36284639 DOI: 10.1002/rth2.12814] [Reference Citation Analysis]
4 Graciaa S, Adeagbo S, Fong G, Rollins M, McElfresh P, Zerra PE, Bennett C, Josephson CD, Briones M, Fasano RM, Chonat S. Clinical features and neurological outcomes in pediatric immune-mediated thrombotic thrombocytopenic purpura: A report from a large pediatric hematology center. Pediatr Blood Cancer 2022;:e29992. [PMID: 36151977 DOI: 10.1002/pbc.29992] [Reference Citation Analysis]
5 George JN. Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond. Semin Thromb Hemost 2022. [PMID: 35793688 DOI: 10.1055/s-0042-1749589] [Reference Citation Analysis]
6 Karsenty CL, Kirk SE, Helber HL, Esquilin JM, Despotovic JM, Grimes AB. Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children. Front Immunol 2022;13:836960. [DOI: 10.3389/fimmu.2022.836960] [Reference Citation Analysis]
7 Fujimura Y, Holland LZ. COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm. Int J Hematol 2022. [PMID: 35316498 DOI: 10.1007/s12185-022-03324-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Fodil S, Zafrani L. Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients. JCM 2022;11:1103. [DOI: 10.3390/jcm11041103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Subhan M, Scully M. Advances in the management of TTP. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Perez Botero J, Reese JA, George JN, McIntosh JJ. Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. Am J Hematol 2021;96:1655-65. [PMID: 34424560 DOI: 10.1002/ajh.26328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Zheng XL. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost 2021;19:1864-71. [PMID: 34060225 DOI: 10.1111/jth.15406] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Scully M. Congenital TTP: next stop, acuity and therapy. Blood 2021;137:3469-71. [PMID: 34165543 DOI: 10.1182/blood.2021011265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sakai K, Fujimura Y, Miyata T, Isonishi A, Kokame K, Matsumoto M. Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort. Br J Haematol 2021;194:444-52. [PMID: 34046888 DOI: 10.1111/bjh.17560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]